| The 4G/5G promotor polymorphism of the plasminogen activator inhibitor-1 gene and late lumen loss after coronary stent placement in smoking and nonsmoking patients. | |
| | |
MedLine Citation:
|
PMID: 11558839 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Instent restenosis remains a significant clinical problem. Identification of patients at risk for instent restenosis may allow selection of individualized appropriate therapeutic approaches. Genetic polymorphisms have been suggested to be associated with the risk of instent restenosis. Smoking is known to influence hemostatic parameters. HYPOTHESIS: This study investigated the influence of the 4G/5G promotor polymorphism of the plasminogen activator inhibitor type I (PAI-1) gene on instent restenosis in smoking and nonsmoking patients. METHODS: In all, 300 consecutive patients (133 nonsmoking; 167 smoking) with elective coronary stent placement and 6-month angiographic follow-up were studied. Quantitative coronary angiography and genotyping with polymerase chain reaction analysis were performed in all patients. RESULTS: Nonsmoking PAI-1 4G/4G carriers showed a significantly greater late lumen loss (n = 38; 0.54 +/- 0.53 mm) compared with nonsmoking PAI-1 4G/5G (n = 68; 0.38 +/- 0.45 mm) or 5G/5G (n = 27; 0.19 +/- 0.23 mm) carriers, analysis of variance (ANOVA) p < 0.001. Smoking patients with the genotypes 4G/4G (n = 46; 0.53 +/- 0.54 mm) and 4G/5G (n = 79; 0.37 +/- 0.41 mm) had a late loss similar to that of nonsmoking patients. Smoking 5G/5G carriers had the highest late loss of all smoking patients (n = 42; 0.63 +/- 0.50); ANOVA p < 0.05; nonsmoking 5G/5G vs. smoking 5G/5G p < 0.001. CONCLUSION: The promotor polymorphism of the PAI-1 gene has a significant influence on instent restenosis after coronary stent implantation. The 5G/5G genotype predisposes nonsmoking gene carriers to less late lumen loss, whereas in smoking gene carriers this genotype is associated with the greatest late lumen loss. This might be explained by an altered expression pattern of hemostatic parameters. |
| | |
Authors:
|
J R Ortlepp; R Hoffmann; A Killian; J Lauscher; S Merkelbach-Brese; P Hanrath |
Related Documents
:
|
15227729 - Association of the gene polymorphisms of platelet glycoprotein ia and iib/iiia with myo... 10607199 - Coronary heart disease and upper airway obstruction. 9462409 - Chronotherapy for coronary heart disease. 15459589 - Short alleles of p-selectin glycoprotein ligand-1 protect against premature myocardial ... 6152569 - Psychological stress and cardiovascular diseases. 9273929 - Relation between body height and self-reported myocardial infarction in germany. 21757479 - Coronary steal detected by transthoracic doppler echocardiography. 21814559 - Different factors affecting human anp amyloid aggregation and their implications in con... 20631859 - A meta-analysis of glucose-insulin-potassium therapy for treatment of acute myocardial ... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical cardiology Volume: 24 ISSN: 0160-9289 ISO Abbreviation: Clin Cardiol Publication Date: 2001 Sep |
Date Detail:
|
Created Date: 2001-09-17 Completed Date: 2002-01-11 Revised Date: 2008-11-21 |
Medline Journal Info:
|
Nlm Unique ID: 7903272 Medline TA: Clin Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 585-91 Citation Subset: IM |
Affiliation:
|
Medical Clinic I, University Hospital of Aachen, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Coronary Disease / complications, radiography, surgery* Coronary Restenosis / etiology, genetics Female Follow-Up Studies Gene Frequency / genetics Genotype Humans Male Middle Aged Multivariate Analysis Plasminogen Activator Inhibitor 1 / genetics* Polymorphism, Genetic / genetics Predictive Value of Tests Promoter Regions, Genetic / genetics* Smoking / genetics* Stents* |
| Chemical | |
Reg. No./Substance:
|
0/Plasminogen Activator Inhibitor 1 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Issues in the assessment of the safety and efficacy of tenecteplase (TNK-tPA).
Next Document: Safety and potential cost savings of same-setting electrophysiologic testing and placement of transv...